[Discussion] survodutide is doing more work than we give it credit for
survodutide is doing more work than we give it credit for. I have gone back and forth on this for months.
What this compound is actually being developed for, since the boards treat it as a weight-loss molecule with a footnote.
It is a dual GLP-1 and glucagon receptor agonist, and the glucagon arm links to hepatic fat and energy expenditure. The headline programme is metabolic liver disease, with endpoints scored on biopsy rather than on a scale.
That matters for how the data should be read. A histological response rate in a biopsy-confirmed population answers a very different question from a mean weight change in an obesity trial, and quoting one in place of the other — which happens in nearly every thread here — is not a comparison.
Looked for independent results across this whole site and found almost none. Worth knowing before forming an opinion.
Asked here what the difference was between the imaging and biopsy endpoints and got a genuinely excellent answer.
Research-use-only material is not approved for human use and nothing here should be read as a recommendation to use it.
best — the order this archive was captured in
Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use.
MASH endpoints are histological, which is a much harder bar
Cosigning on the glucagon arm. It is the mechanistic thread that connects the hepatic and the metabolic effects.
Agreed. The hepatic programme is the point of this compound and the weight discussion is a side effect of the side effect.
Independent result logged. There are almost none for this compound, so it is genuinely valuable.